Research programme: HIV-1 capsid assembly inhibitors - Boehringer-Ingelheim

Drug Profile

Research programme: HIV-1 capsid assembly inhibitors - Boehringer-Ingelheim

Alternative Names: CA assembly inhibitors

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class
  • Mechanism of Action Capsid protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in HIV-1-infections in Canada
  • 16 Feb 2010 Early research in HIV-1 infections in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top